1. Home
  2. VRAX vs ENSC Comparison

VRAX vs ENSC Comparison

Compare VRAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$0.33

Market Cap

2.9M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.01

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
ENSC
Founded
2013
2003
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
6.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VRAX
ENSC
Price
$0.33
$1.01
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
15.4M
418.0K
Earning Date
01-01-0001
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,986.00
$4,487,973.00
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.35
$1.08
52 Week High
$3.20
$9.88

Technical Indicators

Market Signals
Indicator
VRAX
ENSC
Relative Strength Index (RSI) 35.50 24.87
Support Level $0.35 $1.08
Resistance Level $0.43 $1.24
Average True Range (ATR) 0.04 0.13
MACD -0.01 -0.01
Stochastic Oscillator 4.93 2.72

Price Performance

Historical Comparison
VRAX
ENSC

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: